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Abstract
Background: Gain in VO2 peak after cardiac rehabilitation (CR) following an acute coronary syndrome (ACS),
is associated with reduced mortality and morbidity. We have previously shown in CR, that gain in VO2 peak is
reduced in Type 2 diabetic patients and that response to CR is impaired by hyperglycemia.
Methods: We set up a prospective multicenter study (DARE) whose primary objective was to determine whether
good glycemic control during CR may improve the gain in VO2 peak. Sixty four type 2 diabetic patients, referred to
CR after a recent ACS, were randomized to insulin intensive therapy or a control group with continuation of the
pre-CR antidiabetic treatment. The primary objective was to study the effect of glycemic control during CR on the
improvement of peak VO2 by comparing first the 2 treatment groups (insulin intensive vs. control) and second,
2 pre-specified glycemic control groups according to the final fructosamine level (below and above the median).
Results: At the end of the CR program, the gain in VO2 peak and the final fructosamine level (assessing glycemic
level during CR) were not different between the 2 treatment groups. However, patients who had final fructosamine
level below the median value, assessing good glycemic control during CR, showed significantly higher gain in VO2
peak (3.5 ± 2.4 vs. 1.7 ± 2.4 ml/kg/min,p = 0.014) and ventilatory threshold (2.7 ± 2.5 vs. 1.2 ± 1.9 ml/kg/min,p = 0.04)
and a higher proportion of good CR-responders (relative gain in VO2 peak ≥ 16 %): 66 % vs. 36 %, p = 0.011.
In multivariate analysis, gain in VO2 peak was associated with final fructosamine level (p = 0.010) but not with age,
gender, duration of diabetes, type of ACS, insulin treatment or basal fructosamine.
Conclusions: The DARE study shows that, in type 2 diabetes, good glycemic control during CR is an independent
factor associated with gain in VO2 peak. This emphasizes the need for good glycemic control in CR for type 2
diabetic patients.
Trial registration: Trial registered as NCT00354237 (19 July 2006).
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Background
Several studies have clearly shown that cardiac rehabili-
tation (CR) significantly reduces cardiovascular morbid-
ity and mortality and improves quality of life. The clear
benefit of CR on overall mortality and cardiovascular
mortality has been confirmed by several clinical trials
[1, 2], meta-analyses [3–8] and population-based surveil-
lance studies [9]. The cardiovascular mortality rate in
patients who underwent CR with exercise training after
MI was found to be 20 % to 26 % lower than in those
who did not attend a CR program [3, 4, 8]. Long-term
reduction in cardiac and total mortality after CR was
confirmed by Hedbäck et al., who showed a 26.7 % re-
duction in total mortality and a 27.1 % reduction in car-
diovascular mortality over a 10-year period [10]. Hence,
CR programs are recognized as an integral part of the
care strategy for patients with coronary heart disease,
heart failure, cardiac surgery and peripheral artery dis-
ease, and CR is a class I recommendation in patients
with coronary heart disease [11–15].
Exercise capacity is an independent factor reducing
overall and cardiovascular mortality [16]. One of the re-
sults of CR is to improve exercise capacity (assessed on
peak oxygen uptake [peak VO2]), in patients with estab-
lished coronary heart disease. It has been reported, based
on a long-term prognosis study in 12 169 men in CR, that
exercise capacity, determined by direct measurement of
peak VO2, exerts a major long-term influence on progno-
sis in patients after Myocardial Infarction (MI) or ischae-
mic heart disease, with a 9 % improvement in prognosis
for 1-ml/kg/mn increment in peak VO2 [17]. Vanhees et
al. have demonstrated that peak VO2 improvement after
CR reduced significantly cardiovascular morbidity and
mortality in coronary patients [18]. All these data indicate
that a part of the benefit of CR on cardiovascular morbid-
ity and mortality is related to VO2 improvement.
It is well established that cardiovascular disease is the
major cause of morbidity and mortality in patients with
type 2 diabetes and that coronary disease risk is 2–4 fold
increased over non-diabetic subjects [19]. In addition,
prognosis after MI is worse in diabetic patients than in
non-diabetic subjects [20]. Due to their high cardiovascu-
lar risk, patients with type 2 diabetes are highly recom-
mended for CR. However, several studies have shown that
CR is less effective in patients with diabetes [21–24]. Our
group has previously shown that gain in VO2 peak in CR,
after an acute ischaemic heart event, was significantly less
in patients with type 2 diabetes than in non-diabetic
patients (13 % vs. 30 %, p = 0.002) [24]. In addition, we
found an inverse relation between fasting blood glucose
and change in VO2 peak on both univariate (r = −0.40,
p = 0.002) and multivariate (p = 0.001) analyses suggest-
ing that response to CR may be impaired by poor
glycemic control [24].
This prompted us to set up a prospective multicenter
study (the DARE [Diabetes in cArdiac REhabilitation]
Study) in order to determine whether good glycemic
control during CR may improve the gain in VO2 peak.
Methods
Patients
We recruited 64 type 2 diabetic patients enrolled in CR
early after a recent (in the 4 previous weeks) acute cor-
onary syndrome (ACS), treated by percutaneous coron-
ary intervention. Type 2 diabetes was defined according
to the American Diabetes Association criteria (at least 2
fasting blood glucose values above 7.0 mmol/L or
126 mg/dl). All patients had an HbA1c level above 7 %
at time of referral to CR.
Patients who had been treated by coronary bypass sur-
gery, with renal failure (glomerular filtration rate below
30 ml/min), severe peripheral arterial disease (Leriche-
Fontaine stage ≥ 3) severe respiratory failure and those
unable to perform exercise testing and training were not
included in the study.
Before starting the CR program, the patients were ran-
domized either in an intensive treatment group with
basal-bolus insulin therapy or in a control treatment
group in which the antidiabetic treatment at time of en-
rolment in the study was maintained.
In the intensive treatment group, patients received a
daily injection of basal insulin glargine (Lantus®) admin-
istered before dinner and an injection of a rapid-acting
insulin analogue aspart (Novorapid®) bolus before each
meal. The insulin regimen was set up by a diabetologist
before the beginning of the CR program. The initial
basal insulin dose was calculated according to body
weight, gender and fasting blood glucose using the algo-
rithm recommended by Holman and Turner [25, 26].
The initial bolus prandial dose was 1/3 of the basal insu-
lin dose. The patients of the intensive treatment group
were asked to perform self monitoring of blood glucose
(SMBG) 6 times a day (pre and post breakfast, pre and
post lunch, pre and post dinner). During the study, titra-
tion was performed according to the algorithm from the
“treat to target” trial [27] for the basal insulin dose and
according to the post-prandial blood glucose values for
the prandial bolus insulin doses. In this patient group
the capillary blood glucose targets have been defined ac-
cording to the IDF/Europe recommendations: fasting ca-
pillary glucose <1.00 g/l (5.5 mmol/l) and post-prandial
capillary glucose <1.35 g/l (7.5 mmol/l) [28]. Education
on diabetes, including insulin injection and SMBG, was
performed in all the patients from the intensive treat-
ment group. A diabetologist was contacted at least once
a week for the patients of the intensive treatment group.
Patients from the intensive treatment group were also
allowed to be treated with metformin on top of insulin
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when all other antidiabetic treatments were stopped
during the study.
In the control group, the antidiabetic treatment at
time of enrolment in the study was maintained. During
the CR period, modification of the antidiabetic treatment
was permitted in order to avoid hypoglycemic events or
major hyperglycemias.
The primary objective of the DARE study was to
examine the effect of strict glycemic control during CR,
following an ACS, on the improvement of peak VO2.
For this purpose, we planned to compare prospectively
the improvement of peak VO2 during CR first, between
the patients randomized in the intensive insulin treat-
ment group versus the patients randomized in the con-
trol treatment group, second between the patients who
showed good glycemic control during the CR period
(final fructosamine below the median value) versus those
who showed unsatisfactory glycemic control during the
CR period (final fructosamine above the median value).
The secondary objectives were to evaluate the effect of
strict glycemic control during cardiac rehabilitation on
the improvement of ventilatory threshold and on the
number of patients considered as “CR responders”
(showing a relative gain in VO2 peak ≥ 16 %).
Each subject gave written informed consent before
participation in the study, which has been approved by
the Dijon Ethics Committee and has been registered
(trial registered as NCT00354237).
Cardiac rehabilitation program
At the beginning and at the end of the CR program,
each patient underwent a cardiopulmonary exercise test
performed on a cycle ergometer. This symptom limited
cardiopulmonary exercise test started with an initial
workload of 20 watts with increments of 10 watts at
each 1-min exercise stage. During that test, peak VO2
(ml/kg/min) and ventilatory threshold (ml/kg/min) were
measured. Ventilatory and gas exchange data were deter-
mined on a breath-by-breath basis with a computerized
system. Peak oxygen consumption (peak VO2) was de-
fined as the highest consecutive 30-s averaged value ob-
tained during exercise test [29]. Ventilatory Threshold
was estimated by the Wasserman method as the point
where ventilatory equivalent ratio for oxygen (VE/VO2)
starts to increase without concomitant increase in the venti-
latory equivalent ratio for carbon dioxide (VE/VCO2) [30].
The CR program, typical of a post-ACS CR program,
consisted in 20 physical training sessions realized in a
period shorter than 8 weeks. Each session included a
30 min period on bicycle with a training heart rate (HR)
corresponding to the HR obtained at the first ventilatory
threshold during the initial bicycle exercise test accord-
ing to the usual CR recommendations [12]. Moreover,
during therapeutic training, exercise intensity target was
also based on the rating of perceived exertion (RPE),
usually between 12 and 14 on the Borg’s scale [14]. All
the patients were informed how to use the Borg’s scale
before training. Each session was supervised by a skilled
team including cardiologists, cardiovascular nurse spe-
cialists and exercise physiologists. All the patients in-
cluded in the DARE study had a similar CR program.
As usually accepted, patients were considered as “CR-
responder” when their relative increase in peak V02 after
CR was equal or more than 16 % [31].
Metabolic evaluation
At the beginning and at the end of the CR program, fast-
ing blood samples were collected for evaluation of fast-
ing glucose, HbA1c and fructosamine. Fructosamine is
an estimate of mean glycemic level during the 2–3 previ-
ous weeks [32], when HbA1c is an estimate of mean gly-
cemic level during a much longer period of 3 months.
Thus, because the CR program was limited to a 4–8
week period of time, fructosamine at the end of the CR
program, instead of HbA1c, was used to assess mean
glycemic level during CR.
Statistical analysis
Data are expressed as means ± Standard Deviation. Statis-
tical calculations were performed using the SPSS software
package (SPSS Inc., Chicago IL, USA). Comparisons of
means between groups were performed by two-tailed Stu-
dent’s t-test. Comparisons of percentages between groups
were performed by Chi-2 test. When comparing percent-
ages with an expected count smaller than 5 in the 2 × 2
contingency table, the Chi-2 with the Yates correction was
used. Baseline and post-cardiac rehabilitation data were
compared by paired t-test. The correlation coefficients (r)
were determined by linear regression analysis. Statistical
significance of the correlation coefficients was determined
by the method of Fisher and Yates. Multivariable analysis
was performed by stepwise linear regression for continu-
ous dependent variables or by stepwise logistic regression




Among the 64 patients included in the study, 57 com-
pleted the study. The drop out of 7 patients was due to
personal reasons and occurred during the initial period
of the CR program. The baseline data of the patients
who completed the study, in each treatment group (in-
tensive treatment group, control treatment group) are
shown in Table 1. No significant differences were seen
between the 2 groups for gender, age, diabetes duration,
history of previous Coronary Heart Disease (CHD),
tobacco smoking, BMI, type of ACS, resting heart rate,
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systolic and diastolic blood pressure, use of antidiabetic
agents at time of inclusion in the study (metformin, sulfo-
nylurea or glinide, acarbose, pioglitazone, DPP-4 inhibitor,
insulin), use of cardiovascular drugs (ACE inhibitor/ARB,
betablocker, antiplatelet agent, statin), baseline values of
HbA1c, fructosamine, ventilatory threshold and VO2
peak. As far as baseline antidiabetic treatment is con-
cerned, no differences between intensive treatment group
and control treatment group were observed for insulin
program: one daily basal insulin injection (6 vs. 6), two
daily pre-mixed insulin injections (4 vs. 6) and more than
3 daily injections (5 vs. 5). No patients were on insulin
pump. As far as oral antidiabetic drugs (OAD) are
concerned, the number of patients on one OAD, 2 OADs
and 3 or more OADs were 10, 7, 0 and 8, 8, 2 in the con-
trol group and the insulin intensive treatment group re-
spectively (NS).
Results of CR in the whole studied population and in
each treatment group
For the whole diabetic population studied, the mean gain
in VO2 peak after CR was 2.7 ± 2.5 ml/kg/min (16 ±
15 % in relative value).
Among the 57 patients who completed the study, the
compliance was excellent in both groups with a mean
attendance rate of 19.6/20 sessions in the control
Table 1 Baseline characteristics
Control treatment group (n = 31) Intensive treatment group (n = 26)
Gender (M/F) 24/7 22/4 NS
Age (yrs) 58 ± 10 60 ± 10 NS
Diabetes duration (yrs) 7 ± 6 9 ± 8 NS
History of previous CHD 9 (29 %) 6 (23 %) NS
Tobacco smoking n(%) 10 (32 %) 8 (31 %) NS
BMI (kg/m2) 29.9 ± 4.5 29.3 ± 4.1 NS
Type of ACS n(%): NS
- Anterior MI 10 (32.2 %) 10 (38 %)
- Inferior MI 18 (58.0 %) 16 (52 %)
- Lateral MI 2 (6.5 %) 0 (0 %)
- Unstable angina 1 (3.3 %) 0 (0 %)
Heart rate (beats/min) 66 ± 11 63 ± 15 NS
Systolic Blood Pressure (mmHg) 119 ± 18 123 ± 17 NS
Diastolic Blood Pressure (mmHg) 74 ± 12 76 ± 12 NS
Antidiabetic treatment at inclusion n(%): NS
• metformin 9 (29 %) 11 (42 %)
• Sulfonylurea or glinide 11 (35 %) 15 (58 %) NS
• acarbose 1 (3 %) 1 (4 %) NS
• DPP-4 inhibitor 1 (3 %) 2 (8 %) NS
• pioglitazone 0 (0 %) 2 (8 %) NS
• insulin 17 (55 %) 15 (58 %) NS
Cardiovascular drugs n(%):
• ACE inhibitor/ARB 28 (90 %) 24 (92 %) NS
• Beta-blocker 26 (84 %) 22 (85 %) NS
• Antiplatelet agents 31 (100 %) 26 (100 %) NS
• statin 29 (94 %) 25 (96 %) NS
Baseline HbA1c (%) 8.2 ± 1.4 8.4 ± 1.2 NS
Baseline fructosamine (μmol/l) 274 ± 45 278 ± 52 NS
Baseline fasting glucose (mg/dl) 152 ± 42 164 ± 104 NS
Baseline VO2 peak (ml/kg/min) 17.4 ± 4.7 16.5 ± 3.8 NS
Baseline ventilatory threshold (ml/kg/min) 12.6 ± 4.0 12.2 ± 3.9 NS
Data are means ± SD or n (%)
CHD coronary heart disease, ACS, acute coronary syndrome, MI myocardial infarction, ACE angiotensin-converting-enzyme, ARB angiotensin receptor blocker
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treatment group and of 19.8/20 sessions in the intensive
treatment group.
The results of CR for each treatment group are shown
in Table 2. The final values of the VO2 peak or the ven-
tilatory threshold as well as the gain in VO2 peak or
ventilatory threshold were not different between the 2
treatment groups. Similarly, mean final values of fructo-
samine at the end of CR were not different between the
2 groups. The mean reduction in plasma fructosamine
level was not significantly different between the two
groups (−37 ± 46 vs.-31 ± 40 μmol/l, p = 0,44). As ex-
pected, 100 % of the patients in the intensive treatment
group were receiving insulin during CR, whereas 55 % of
the patients were on insulin in the control treatment
group. In the patients on insulin, the mean insulin dose
was not significantly different between the 2 treatment
groups. Body weight was not significantly modified after
CR in both groups.
Only 5 minor hypoglycemic events were recorded dur-
ing the study in the intensive treatment group and no
serious hypoglycemic event occurred.
Results of CR according to the glucose control during CR
To analyse the effect of glycemic control during CR on
the results of CR, we compared the data between two
pre-specified groups according to the final fructosamine
level. Patients who had a final fructosamine level below
the median value (240 μmol/l), indicating good glycemic
control during CR, showed, as compared to those with a
final fructosamine level above the median value, signifi-
cantly higher gain in VO2 peak (3.5 ± 2.5 vs. 1.7 ±
2.4 ml/kg/min, p = 0.014) and in ventilatory threshold
(2.7 ± 2.5 vs. 1.2 ± 1.9 ml/kg/min, p = 0.04) as shown in
Fig. 1. The percentage of “CR responders” (showing a
relative gain in VO2 peak ≥ 16 %) was significantly
higher among the patients with final fructosamine below
the median value than among those with final fructosa-
mine above the median value (66 % vs. 36 %, p = 0.011)
(Table 3).
The characteristics of the patients with final fructosa-
mine below the median value and those with the final
fructosamine level above the median value are shown in
Table 3. Age, duration of diabetes, history of previous
CHD, tobacco smoking, type of ACS, baseline antidia-
betic treatment, cardiovascular drug use, baseline VO2
peak, baseline ventilatory threshold, insulin use during
CR and mean insulin dose in the insulin-treated patients
were similar in the 2 groups. Baseline and final HbA1c
as well as baseline fructosamine values were significantly
higher in the patients with final fructosamine level above
the median value, compared to those with final fructosa-
mine level below the median value. As expected, mean
final fructosamine was higher in the patients with final
fructosamine level above the median value. Mean BMI
was lower and the percentage of women higher in the
group of patients with final fructosamine level above the
median value.
Factors influencing gain in VO2 peak during CR
In univariate analysis, gain in VO2 peak after CR was
negatively correlated with basal (r = −0.31, p = 0.017) and
final fructosamine (r = −0.36, p = 0.005) and with basal
(r = −0.36, p = 0.005) and final HbA1c (r = −0.33, p =
0.013). Gain in VO2 peak was not correlated with age,
duration of diabetes nor with BMI. The mean gain in
VO2 peak was not significantly different between men
and women (+2.9 ± 2.4 vs. + 1.7 ± 2.7 ml/kg/min, p =
0.20). The mean gain in VO2 peak was not different
Table 2 MeanVO2 peak, ventilatory threshold and fructosamine values before and after CR for each treatment group
Control treatment group (n = 31) Intensive treatment group (n = 26) p
Baseline VO2 peak (ml/kg/min) 17.4 ± 4.7 16.5 ± 3.8 NS
End-CR VO2 peak (ml/kg/ min) 20.5 ± 5.4 19.2 ± 5.0 NS
Baseline ventilatory threshold (ml/kg/min) 12.6 ± 4.0 12.2 ± 3.9 NS
End-CR ventilatory threshold (ml/kg/ min) 15.0 ± 5.0 14.3 ± 4.6 NS
Gain in VO2 peak (ml/kg/min) 2.7 ± 2.8 2.6 ± 2.2 NS
Gain in ventilatory threshold (ml/kg/min) 2.2 ± 2.4 2.2 ± 2.5 NS
Baseline fructosamine (μmol/l) 274 ± 45 278 ± 52 NS
End-CR fructosamine (μmol/l) 244 ± 41 240 ± 41 NS
Baseline fasting glucose (mg/dl) 152 ± 42 164 ± 104 NS
End-CR fasting glucose (mg/dl) 133 ± 32 126 ± 25 NS
Patients on insulin during CR 17 (55 %) 26 (100 %) <0.0001
Mean insulin dose in insulin-treated patients (UI/day) 38 ± 25 44 ± 26 NS
Patients on metformin during CR 12 (39 %) 4 (15 %) 0.051
Data are means ± SD or n (%)
CR cardiac rehabilitation
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between patients with anterior MI versus those with
other location of MI, between patients with and without
history of previous CHD, nor between patients who re-
ceived insulin treatment during CR versus those who did
not.
In multivariable analysis, gain in VO2 peak was sig-
nificantly negatively associated with final fructosamine
(β = −357, p = 0.010) but not with age, gender, baseline
fructosamine, diabetes duration, BMI, basal VO2 peak,
type of SCA, treatment group (insulin intensive/control)
or insulin treatment during CR (Table 4). When final
fructosamine value was replaced in the statistical model
by the qualitative variable “fructosamine above the median
value” (yes or no), the latter was significantly negatively
associated with final fructosamine (β = −342, p = 0.014)
whereas the other variables were not (Table 4).
In mutivariate analysis, CR-response (relative gain in
VO2 peak ≥16 %) was significantly negatively associated
with final fructosamine (Wald = 4.22, p = 0.040) but not
with age, gender, baseline fructosamine, diabetes dur-
ation, BMI, treatment group (insulin intensive/control)
or insulin treatment during CR. When final fructosa-
mine value was replaced in the statistical model by the
qualitative variable “fructosamine above the median
value” (yes or no), the latter was significantly negatively
associated with final fructosamine (Wald = 4.86, p = 0.028)
whereas the other variables were not.
Discussion
Here we present the results of the DARE study, which is
the first intervention study aiming to determine whether
good glycemic control during CR may improve the gain
in VO2 peak. We demonstrate that patients with good
glycemic control during CR show a significantly higher
gain in VO2 peak than those with less good glycemic
control. In addition, we demonstrate that final fructosa-
mine level, reflecting glycemic control during CR, is an
independent factor influencing gain in VO2 peak.
In the present study, only 7 patients did not complete
the cardiac rehabilitation program for personal reasons,
representing a drop-out rate of 11 %. This is lower than
drop-out rates reported in some studies [33, 34], but
similar to the drop-out rate stated by Wittmer et al. [35].
In order to assess mean glycemic level during CR, we
used fructosamine level at the end of the CR program.
Indeed, fructosamine, which is an estimate of mean gly-
cemic level during the 2–3 previous weeks [32] is more
appropriate to assess mean blood glucose level during
the CR period (which was shorter than 8 weeks) than
HbA1c, reflecting mean glycemic level during the 3 pre-
vious months. In clinical practice, fructosamine level is
used in situations such as pregnancy for which short
term assessment of mean glycemic level is needed [32].
Patients who had final fructosamine level below the
median value showed a significant larger gain in VO2
peak than those having final fructosamine level above
the median. It is interesting to note that patients with
final fructosamine below the median had a mean final
fructosamine level of 213 μmol/l, indicating good gly-
cemic control during CR. In addition, as shown by the
multivariate analysis, final fructosamine level is a strong
independent determinant for gain in VO2 peak during
CR. Moreover, final fructosamine level is shown to be a
significant independent predictor of the response to CR.
Together, these data indicate that good glycemic control
during CR is an important factor contributing to the
Fig. 1 Gain in VO2 peak and ventilatory threshold during CR in patients with final fructosamine level below the median value and in patients
with final fructosamine level above the median value
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optimal gain in VO2 peak independently of other factors
including baseline glucose control as demonstrated by
the multivariate analysis. We have to note that patients
who had final fructosamine level below the median value
showed a slightly higher BMI than those who had final
fructosamine level above the median value. We have no
clear explanations for that. However, this difference in
BMI between the 2 groups is not likely to have influ-
enced the gain in VO2 peak since BMI has been taken
into account in the multivariate analysis demonstrating
the independent association between good glycemic con-
trol during CR and gain in VO2 peak.
When comparing the patients included in the intensive
treatment group with those included in the control
Table 3 Characteristics of the patients with final fructosamine below the median value and of the patients with final fructosamine
above the median value
Final fructosamine level below median
(n = 29)
Final fructosamine level above median
(n = 28)
p
Gender (M/F) 27/2 19/9 0.039
Age (yrs) 59 ± 10 59 ± 8 NS
Diabetes duration (yrs) 7 ± 7 9 ± 8 NS
History of previous CHD 8 (26 %) 7 (26 %) NS
Tobacco smoking n(%) 10 (34 %) 8 (29 %) NS
BMI (kg/m2) 31.0 ± 4.5 28.6 ± 3.6 0.048
Type of ACS n(%): NS
- Anterior MI 12 (41.4 %) 8 (28.6 %)
- Inferior MI 16 (55.2 %) 18 (64.2 %)
- Lateral MI 1 (3.4 %) 1 (3.6 %)
- Unstable angina 0 (0 %) 1 (3.6 %)
Antidiabetic treatment at inclusion n(%): NS
• Metformin 12 (41 %) 8 (29 %)
• Sulfonylurea or glinide 14 (48 %) 12 (43 %) NS
• Acarbose 0 (0 %) 2 (7 %) NS
• dpp4 inhibitor 1 (3 %) 2 (7 %) NS
• Pioglitazone 1 (3 %) 1 (4 %) NS
• Insulin 15 (52 %) 17 (61 %) NS
Cardiovascular drugs n(%): NS
• Statin 27 (93 %) 27 (96 %)
• ACE/inhibitor/ARB 28 (96 %) 24 (86 %) NS
• Beta-blocker 25 (86 %) 23 (82 %) NS
• Antiplatelet agents 29 (100 %) 28 (100 %) NS
Baseline HbA1c (%) 7.9 ± 1.1 8.8 ± 1.4 0.015
Baseline fructosamine (μmol/l) 253 ± 40 297 ± 51 0.0001
Baseline VO2 peak (ml/kg/min) 17.1 ± 4.1 17.1 ± 4.7 NS
Baseline ventilatory threshold (ml/kg/min) 12.4 ± 3.2 12.4 ± 4.8 NS
Final (End-CR) fasting glucose (mg/dl) 119 ± 21 152 ± 32 0.005
Final (End-CR) HbA1c (%) 6.8 ± 0.9 7.9 ± 1.0 <0.0001
Final (End-CR) fructosamine (μmol/l) 213 ± 17 274 ± 29 <0.0001
Gain in VO2 peak (ml/kg/min) 3.5 ± 2.4 1.7 ± 2.4 0.014
Gain in ventilatory threshold (ml/kg/min) 2.7 ± 2.5 1.2 ± 1.9 0.040
CR responders n (%) 19 (66 %) 10 (36 %) 0.011
Patients on insulin during CR 22 (76 %) 25 (89 %) NS
Mean insulin dose in insulin-treated patients (UI/day) 38 ± 24 46 ± 30 NS
CHD coronary heart disease; ACS acute coronary syndrome, MI myocardial Infarction; ACE angiotensin-converting-enzyme; ARB angiotensin receptor blocker;
CR cardiac rehabilitation
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group, we did not find any difference in gain in VO2
peak during CR. This is likely to be due to the fact that
glycemic control was identical between the 2 groups.
This reinforces the data of our multivariate analysis
showing that final fructosamine, assessing glucose con-
trol during CR, is a significant independent factor asso-
ciated with gain in VO2 peak, when insulin treatment is
not. This indicates that good glycemic control during
CR influences positively the gain in VO2 peak whatever
the antidiabetic treatment used.
Although some studies did not report reduced efficacy of
CR on exercise capacity in patients with diabetes [36, 33],
several other studies have shown that CR is less effective in
patients with diabetes [21–24]. These discrepancies could
be due to differences in ethnicity, in glycemic control and
in control groups. In a previous study, we found that fast-
ing blood glucose was an independent factor influencing
gain in VO2 peak during CR [24]. In the present prospect-
ive study, we demonstrate that good glycemic control dur-
ing CR improves significantly the gain in VO2 peak. Our
results are in line with a recent study which showed a
negative correlation between HbA1c and improvement in
knee extensor muscle strength in patients undergoing CR
after coronary artery bypass graft surgery [37] and with
another one which reported an independent negative asso-
ciation between HbA1c and exercise capacity, during exer-
cise stress testing, in patients with type 2 diabetes [38]. All
together, these data give emphasis to the detrimental effect
of hyperglycaemia on the improvement of exercise capacity
during CR. Accumulating evidence suggests the unfavour-
able effect of hyperglycemia on cardiomyocytes and mus-
cles that may participate in changes on exercise capacity
(VO2). Indeed, hyperglycemia has been shown, in vitro, to
increase reactive oxygen species in the cardiomyocytes
leading to myocardial apoptosis [39–41]. Hyperglycemia
also stimulates myocardial endoplasmic reticulum (ER)
stress which has been shown to promote cardiomyocyte
dysfunction and to contribute to cardiomyopathy in dia-
betic rats [42, 43]. Several studies have shown impairment
of cardiomyocyte calcium cycling induced by hypergly-
cemia [44–46]. In vitro, cardiomyocytes maintained in a
high glucose concentration culture medium exhibit slower
cytosolic Ca++ clearing, prolonged action potentials and
prolonged relaxation after only one day [44]. Hypergly-
cemia has also been shown, in vitro, to increase the O-
GlcNAcylation of nuclear proteins in the cardiomyocytes
leading to impair calcium cycling [46]. Furthermore, in cul-
ture myocytes, high glucose promotes the degradation of
the transcription factor GATA4 essential for cardiomyo-
cyte growth and survival [47]. Moreover, it has been dem-
onstrated that hyperglycemia reduces the expression of
caveolin-3 in the cardiomyocytes through protein kinase C
β2 activation leading to diastolic cardiac dysfunction [48].
Interestingly, control of plasma glucose attenuates oxi-
dative stress and slows the progression of heart failure in
mice [49].
In addition to cardiomyocyte dysfunction, skeletal muscle
dysfunction induced by hyperglycemia may also play a role.
Indeed, an impaired functional capacity of mitochondria in
skeletal muscle is observed in type 2 diabetes [50]. In
addition, decreased skeletal muscle strength has been re-
ported in patients with diabetes, directly correlated with
HbA1c [37].
Glycation of haemoglobin, itself, could also play a role
in reduced gain in VO2 peak in patients with uncontrolled
diabetes. Indeed, it has recently been shown that patients
with type 1 diabetes free from clinical micro- and macro-
angiopathy but with poor glycemic control showed during
exercise lower VO2 peak and a blunted deoxyhaemoglobin
(HHb) increase, indicating lower muscle oxygen extrac-
tion, suggesting higher oxygen affinity of glycated haemo-
globin [51].
We note that in our present study intensive treatment
with insulin is not superior to the usual antidiabetic treat-
ment. This indicates that in type 2 diabetes, intensive
Table 4 Multivariable analysis with gain in VO2peak as
dependent variable
Variables β t p
A. Model 1 with age, gender, duration of diabetes, BMI, baseline
fructosamine, final fructosamine, baseline VO2 peak, type of SCA and
treatment group (insulin intensive/control) as independent variables
Final fructosamine −0.357 −2.680 0.010
Age −0.086 −0.638 0.527
Gender −0.090 −0.638 0.527
Diabetes duration −0.033 −0.240 0.812
BMI −0.092 −0.651 0.518
Baseline fructosamine −0.167 −1.032 0.307
Baseline VO2 peak 0.123 0.920 0.362
Type of ACS −0.106 −0.786 0.436
Treatment group (insulin intensive/control) −0.038 −0.282 0.779
B. Model 2 (similar to model 1 with the variable “Fructosamine above
the median” instead of “Final fructosamine”)
Fructosamine above median −0.342 −2.549 0.014
Age −0.077 −0.572 0.570
Gender −0.099 −0.695 0.490
Diabetes duration −0.040 −0.295 0.769
BMI −0.083 −0.588 0.559
Baseline fructosamine −0.207 −1.406 0.166
Baseline VO2 peak 0.099 0.736 0.465
Type of ACS −0.184 −1.379 0.174
treatment group (insulin intensive/control) −0.046 −0.338 0.737
β standardized coefficient
ACS acute coronary syndrome
Similar results when the variable “Treatment with insulin” is introduced into
the model instead of “Treatment group (insulin intensive/control)”
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insulin treatment is not suited for all patients. This is likely
due to the fact that several patients with type 2 diabetes
show marked insulin resistance with poor response to in-
sulin treatment. This is the reason why it is suggested to
adopt, in each patient with type 2 diabetes, a personalized
treatment based on the pathophysiological profile of his
diabetes [52].
It has been demonstrated that increased VO2 peak is
associated with decreased cardiovascular and all-cause
mortality [16, 17]. In a long-term prognosis study per-
formed in men with coronary disease, it has been shown
that a 1-ml/kg/min increment in VO2 peak leads to a
9 % reduction of mortality [17]. This improvement of
VO2 peak is an important target in CR in order to re-
duce mortality. The results of the DARE study clearly
show that good glycemic control during CR is important
to optimize the gain in VO2 peak. Thus, it seems im-
portant to pay attention to glycemic control of patients
with diabetes during CR in order to improve their long-
term prognosis.
One limitation of our study is that the results are lim-
ited to a Caucasian population. Additional studies in
non Caucasian populations are needed to know whether
our results may be extrapolated to all ethnic groups.
Conclusions
The DARE study shows that fructosamine level at the
end of the CR-program is an important determinant of
gain in VO2 peak in patients with type 2 diabetes and
that good glycemic control in CR is associated with sig-
nificantly better gain in VO2 peak, independent of the
treatment used (insulin or not). These data indicate that
good glycemic control of type 2 diabetes in CR, after
myocardial infarction, is mandatory in order to get opti-
mal gain in VO2 peak.
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